The gut microbiome: Bridging medications and clinical outcomes post stem cell transplantation

Ziyu Huang; Tao Zuo

doi:10.1016/j.chom.2023.06.012

The gut microbiome: Bridging medications and clinical outcomes post stem cell transplantation

Cell Host Microbe. 2023 Aug 9;31(8):1257-1259. doi: 10.1016/j.chom.2023.06.012.

Authors

Ziyu Huang¹, Tao Zuo²

Affiliations

¹ Key Laboratory of Human Microbiome and Chronic Diseases (Sun Yat-sen University), Ministry of Education, China; Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China.
² Key Laboratory of Human Microbiome and Chronic Diseases (Sun Yat-sen University), Ministry of Education, China; Guangdong Institute of Gastroenterology, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China; Biomedical Innovation Center, The Sixth Affiliated Hospital, Sun Yat-sen University, Guangzhou, China. Electronic address: zuot@mail.sysu.edu.cn.

PMID: 37562360
DOI: 10.1016/j.chom.2023.06.012

Abstract

Anti-cancer therapies are usually intertwined with prolonged use of drugs, which may lead to different clinical outcomes. Recently in Cell and Cell Host & Microbe, Nguyen et al. and Vallet et al., respectively, deconvolute the drug effects on gut microbiome dynamics underpinning clinical outcomes after allogeneic hematopoietic stem cell transplantation.

MeSH terms

Gastrointestinal Microbiome*
Hematopoietic Stem Cell Transplantation*